{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:14:59Z","timestamp":1790176499547,"version":"4.1.0"},"reference-count":93,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,8,17]]},"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the impact of various antiretroviral\/antiviral regimens in pregnant women living with HIV or hepatitis B virus (HBV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We performed random effects meta-analysis for HIV-related outcomes and network meta-analysis for HBV outcomes, and used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to assess quality separately for each outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Embase and Medline to February 2017.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>For maternal outcomes, we considered randomised controlled trials (RCTs) comparing tenofovir-based regimens with those with alternative nucleoside\/nucleotide reverse transcriptase inhibitors (NRTIs). For child outcomes, we included RCTs and comparative observational studies of tenofovir-based regimens versus alternative NRTIs regimens or, for HBV, placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten studies (seven RCTs) met the inclusion criteria for maternal and child outcomes, and an additional 33 studies (12 RCTs) met the inclusion criteria for HBV-specific outcomes. The most common comparison was tenofovir and emtricitabine versus zidovudine and lamivudine. There was no apparent difference between tenofovir-based regimens and alternatives in maternal outcomes, including serious laboratory adverse events (low certainty) and serious clinical adverse events (moderate certainty). There was no difference between NRTIs in vertical transmission of HIV: 1 more per 1000, 8 fewer to 10 more, low certainty; or vertical transmission of HBV: 7 fewer per 1000, 10 fewer to 38 more, moderate certainty. We found moderate certainty evidence that tenofovir\/emtricitabine increases the risk of stillbirths and early neonatal mortality (51 more per 1000, 11 more to 150 more) and the risk of early premature delivery at &lt;34 weeks (42 more per 1000, 2 more to 127 more).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tenofovir\/emtricitabine is likely to increase stillbirth\/early neonatal death and early premature delivery compared with zidovudine\/lamivudine, but certainty is low when they are not coprescribed with lopinavir\/ritonavir. Other outcomes are likely similar between antiretrovirals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42017054392.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2017-019022","type":"journal-article","created":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T15:12:53Z","timestamp":1544541173000},"page":"e019022","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Antiretroviral therapy for pregnant women living with HIV or hepatitis B: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"7","author":[{"given":"Reed A","family":"Siemieniuk","sequence":"first","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Foroutan","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Mirza","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinell","family":"Mah Ming","sequence":"additional","affiliation":[{"name":"Southern Alberta HIV Clinic, Alberta Health Services, Calgary, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E","family":"Alexander","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada"},{"name":"The Infectious Diseases Society of America, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnav","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olufunmilayo","family":"Lesi","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Unit, College of Medicine, University of Lagos and Lagos University Teaching Hospital, Lagos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Merglen","sequence":"additional","affiliation":[{"name":"Division of General Pediatrics, University Hospitals of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Mir","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Hepworth","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung","family":"Lee","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena","family":"Zeraatkar","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon H","family":"Guyatt","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,9,11]]},"reference":[{"key":"2025120518011226000_7.9.e019022.1","unstructured":"World Health Organization. Number of women living with HIV. Geneva, Switzerland: World Health Organization, 2017. http:\/\/www.who.int\/gho\/hiv\/epidemic_status\/cases_adults_women_children\/en\/ (accessed 20 Mar 2017)."},{"key":"2025120518011226000_7.9.e019022.2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199504120-00011"},{"key":"2025120518011226000_7.9.e019022.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.9.1175"},{"key":"2025120518011226000_7.9.e019022.4","unstructured":"UNAIDS. HIV Fact Sheets, 2017. http:\/\/aidsinfo.unaids.org\/ (accessed 20 Mar 2017)."},{"key":"2025120518011226000_7.9.e019022.5","unstructured":"World Health Organization. Prevention of mother-to-child transmission: World Health Organization, 2017. Available from. http:\/\/www.who.int\/gho\/hiv\/epidemic_response\/PMTCT_text\/en\/ (accessed 04 Nov 2017)."},{"key":"2025120518011226000_7.9.e019022.6","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328350995c"},{"key":"2025120518011226000_7.9.e019022.7","unstructured":"World Health Organization. WHO validates elimination of mother-to-child transmission of HIV and syphilis in Cuba, 2015."},{"key":"2025120518011226000_7.9.e019022.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507198"},{"key":"2025120518011226000_7.9.e019022.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506816"},{"key":"2025120518011226000_7.9.e019022.10","unstructured":"World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2nd edition, 2016."},{"key":"2025120518011226000_7.9.e019022.11","unstructured":"Siemieniuk RA , Mah Ming J , Guyatt GH , et al . Antiretroviral therapy for pregnant women living with HIV. BMJ. (Clinical research ed) (Co-submitted)."},{"key":"2025120518011226000_7.9.e019022.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511691"},{"key":"2025120518011226000_7.9.e019022.13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0000000000001359","article-title":"Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis","volume":"76","author":"Nachega","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025120518011226000_7.9.e019022.14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28156"},{"key":"2025120518011226000_7.9.e019022.15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.8735"},{"key":"2025120518011226000_7.9.e019022.16","unstructured":"UNAIDS. On the fast-track to end AIDS: UNAIDS 2016-2021 Strategy. 2015."},{"key":"2025120518011226000_7.9.e019022.17","unstructured":"Fowler MG , Qin M , Fiscus SA , et al , 2015. PROMISE: Efficacy and Safety of 2 Strategies to Prevent Perinatal HIV Transmission. Conference on retroviruses and opportunistic infections. Seattle, USA (Abstract 31LB)."},{"key":"2025120518011226000_7.9.e019022.18","unstructured":"Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. 2016."},{"key":"2025120518011226000_7.9.e019022.19","unstructured":"Lytvyn L , Siemieniuk RA , Guyatt GH , et al . Values and preferences of pregnant women living with HIV considering antiretroviral therapy. BMJ. (Co-submitted)."},{"key":"2025120518011226000_7.9.e019022.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i5191"},{"key":"2025120518011226000_7.9.e019022.21","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)30091-1"},{"key":"2025120518011226000_7.9.e019022.22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28302"},{"key":"2025120518011226000_7.9.e019022.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j576"},{"key":"2025120518011226000_7.9.e019022.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i5085"},{"key":"2025120518011226000_7.9.e019022.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1982"},{"key":"2025120518011226000_7.9.e019022.26","unstructured":"U.S. Department of Health and Human Services,National Institutes of Health, Division of AIDS National Institute of Allergy and Infectious Diseases Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. 2014. version 2.0 ed."},{"key":"2025120518011226000_7.9.e019022.27","unstructured":"Busse JWG G . Modification of Cochrane tool to assess risk of bias in randomized trials 2013. https:\/\/distillercer.com\/wp-content\/uploads\/2014\/02\/Tool-to-Assess-Risk-of-Bias-in-Randomized-Controlled-Trials.docx (accessed July 11, 2016)."},{"key":"2025120518011226000_7.9.e019022.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.04.015"},{"key":"2025120518011226000_7.9.e019022.29","unstructured":"Busse JWG G . Modification of Ottawa-Newcastle tool to assess risk of bias in observational studies 2013. (accessed 11 Jul 2016)."},{"key":"2025120518011226000_7.9.e019022.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2025120518011226000_7.9.e019022.31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5630"},{"key":"2025120518011226000_7.9.e019022.32","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5453"},{"key":"2025120518011226000_7.9.e019022.33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7401"},{"key":"2025120518011226000_7.9.e019022.34","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw439"},{"key":"2025120518011226000_7.9.e019022.35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001290","article-title":"Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings","volume":"9","author":"Campbell","year":"2012","journal-title":"PLoS Med"},{"key":"2025120518011226000_7.9.e019022.36","unstructured":"Bunge K , Balkus J , Noguchi L , et al , 2015. Pregnancy incidence and outcomes in women receiving tenofovir-based PrEP in the VOICE trial. International AIDS conference. Vancouver, Canada (MOPEC480)."},{"key":"2025120518011226000_7.9.e019022.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202614"},{"key":"2025120518011226000_7.9.e019022.38","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","article-title":"Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load","volume":"374","author":"Pan","year":"2016","journal-title":"N Engl J Med"},{"key":"2025120518011226000_7.9.e019022.39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001217","article-title":"Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial","volume":"9","author":"Gibb","year":"2012","journal-title":"PLoS Med"},{"key":"2025120518011226000_7.9.e019022.40","unstructured":"Rough K , Seage GR , Williams PL , et al , 2017. TDF\/FTC in pregnancy shows no increase in adverse infant birth outcomes in US cohorts. Conference on Retroviruses and Opportunistic Infections. Seattle, Washington (Abstract #779)."},{"key":"2025120518011226000_7.9.e019022.41","unstructured":"Zash R , Jacobson D , Diseko M , et al , 2017. Adverse birth outcomes differ by ART regimen from conception in Botswana. Conference on Retroviruses and Opportunistic Infections. Seattle, Washington (Abstract #25)."},{"key":"2025120518011226000_7.9.e019022.42","unstructured":"Antiretroviral Pregnancy Registry Steering Committee. 2016. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2016. Wilmington, USA."},{"key":"2025120518011226000_7.9.e019022.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051871"},{"key":"2025120518011226000_7.9.e019022.44","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.52.9155"},{"key":"2025120518011226000_7.9.e019022.45","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181dd911e"},{"key":"2025120518011226000_7.9.e019022.46","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn471"},{"key":"2025120518011226000_7.9.e019022.47","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir505"},{"key":"2025120518011226000_7.9.e019022.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906768"},{"key":"2025120518011226000_7.9.e019022.49","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832cbcc2"},{"key":"2025120518011226000_7.9.e019022.50","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181f903f8"},{"key":"2025120518011226000_7.9.e019022.51","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis553"},{"key":"2025120518011226000_7.9.e019022.52","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12212"},{"key":"2025120518011226000_7.9.e019022.53","doi-asserted-by":"crossref","first-page":"S295","DOI":"10.1016\/S0168-8278(11)60738-1","article-title":"736 lamivudine in late pregnancy for prevention of hbv transmission: Effectiveness and detection of antiviral resistance","volume":"54","author":"Ayres","year":"2011","journal-title":"J Hepatol"},{"key":"2025120518011226000_7.9.e019022.54","first-page":"S01","article-title":"Preventing mother to child transmission of HBV in an ethnically diverse South London population: an effective multidisciplinary clinical pathway (Abstract)","volume":"63","author":"Carey","year":"2016","journal-title":"Hepatology"},{"key":"2025120518011226000_7.9.e019022.55","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i48.9377"},{"key":"2025120518011226000_7.9.e019022.56","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jhep.2013.10.029","article-title":"Hepatitis B virus infection among HIV-infected pregnant women in Malawi and transmission to infants","volume":"60","author":"Chasela","year":"2014","journal-title":"J Hepatol"},{"key":"2025120518011226000_7.9.e019022.57","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27837"},{"key":"2025120518011226000_7.9.e019022.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.04.038"},{"key":"2025120518011226000_7.9.e019022.59","first-page":"1730","article-title":"Effect of lamivudine treatment combined with active\u2013passive immunization on interrupting mother to infant transmission of HBV","volume":"23","author":"Guo","year":"2008","journal-title":"Clinical Focus"},{"key":"2025120518011226000_7.9.e019022.60","first-page":"673","article-title":"Efficacy and safety of lamivudine treatment on preventing hepatitis B virus vertical transmission in pregnant women","volume":"27","author":"Han","year":"2009","journal-title":"Chin J Infect Dis"},{"key":"2025120518011226000_7.9.e019022.61","first-page":"378","article-title":"Effect and safety of preventing HBV vertical transmission by lamivudine treatment","volume":"44","author":"Han","year":"2005","journal-title":"Chinese J Intern Med"},{"key":"2025120518011226000_7.9.e019022.62","first-page":"1088A","article-title":"Tenofovir Disoproxil: Effective and Safe in Prevention of Mother-to-child Transmission of Hepatitis B Virus","volume":"60","author":"Huang","year":"2014","journal-title":"Hepatology"},{"key":"2025120518011226000_7.9.e019022.63","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/jvh.12436","article-title":"Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region","volume":"23","author":"Samadi Kochaksaraei","year":"2016","journal-title":"J Viral Hepat"},{"key":"2025120518011226000_7.9.e019022.64","first-page":"100","article-title":"Nucleot(s)ide analogues to prevent perinatal transmission of HBV: Lamivudine is effective but tenofovir may be better","volume":"26","author":"Lawler","year":"2011","journal-title":"J Gastro Hepato"},{"key":"2025120518011226000_7.9.e019022.65","first-page":"106","article-title":"Clinical effect and safety of lamivudine in interruption of chronic HBV maternal to infant transmission","volume":"11","author":"Wf","year":"2006","journal-title":"Chin Hepatol"},{"key":"2025120518011226000_7.9.e019022.66","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v9.i7.1501"},{"key":"2025120518011226000_7.9.e019022.67","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.14309\/00000434-201310001-00530","article-title":"Safety of Tenofovir Disoproxil Fumarate Treatment in Late Pregnancy in Highly Viremic Mothers with Chronic Hepatitis B","volume":"108","author":"Pan","year":"2013","journal-title":"J American Gastro"},{"key":"2025120518011226000_7.9.e019022.68","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/jvh.12640","article-title":"Lamivudine therapy during the second vs the third trimester for preventing transmission of chronic hepatitis B","volume":"24","author":"Pan","year":"2017","journal-title":"J Viral Hepat"},{"key":"2025120518011226000_7.9.e019022.69","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0016-5085(14)63498-3","article-title":"Su1007 Tenofovir or Lamivudine Use in Late Pregnancy Safely Reduces Perinatal Transmission of Hepatitis B Virus in Real-Life Practice","volume":"146","author":"Pan","year":"2014","journal-title":"Gastroenterology"},{"issue":"4 Suppl 3","key":"2025120518011226000_7.9.e019022.70","doi-asserted-by":"crossref","first-page":"19632","DOI":"10.7448\/IAS.17.4.19632","article-title":"Hepatitis B virus (HBV) status of children born to HIV\/HBV co-infected women in a French hospital: a cross-sectional study","volume":"17","author":"Sellier","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"2025120518011226000_7.9.e019022.71","first-page":"77","article-title":"Study of lamivudine in interruption of HBV intrauterine infection","volume":"21","author":"Shi","year":"2005","journal-title":"Clin Med Chin"},{"key":"2025120518011226000_7.9.e019022.72","first-page":"181","article-title":"Lamivudine in pregnancy: impact on hepatitis flares and HBeAg seroconversion post partum","volume":"27","author":"Tan","year":"2012","journal-title":"J Gastro Hepato"},{"key":"2025120518011226000_7.9.e019022.73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140070","article-title":"Hepatitis B Virus (HBV) Variants in Untreated and Tenofovir Treated Chronic Hepatitis B (CHB) Patients during Pregnancy and Post-Partum Follow-Up","volume":"10","author":"Virine","year":"2015","journal-title":"PLoS One"},{"key":"2025120518011226000_7.9.e019022.74","first-page":"14","article-title":"Evaluation of therapeutic effect in HBV vertical transmission by lamivudine treatment combined with active-passive immunization for pregnant women","volume":"2","author":"Xiang","year":"2007","journal-title":"Chin Prac Med"},{"key":"2025120518011226000_7.9.e019022.75","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2008.01056.x"},{"key":"2025120518011226000_7.9.e019022.76","first-page":"329","article-title":"Effect of high viral hepatitis B virus DNA loads on vertical transmission of hepatitis B virus in late-pregnant women]","volume":"43","author":"Yang","year":"2008","journal-title":"Zhonghua fu chan ke za zhi"},{"key":"2025120518011226000_7.9.e019022.77","first-page":"1094A","article-title":"Clinical outcomes of tenofovir disoproxil fumarate (TDF) treatment versus no treatment for pregnant women with active chronic hepatitis B (CHB) and elevated alanine aminotransaminase (ALT)","volume":"60","author":"Yi","year":"2014","journal-title":"Hepatology"},{"key":"2025120518011226000_7.9.e019022.78","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jcv.2014.06.005","article-title":"Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus","volume":"61","author":"Mm","year":"2014","journal-title":"J Clin Virol"},{"key":"2025120518011226000_7.9.e019022.79","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/hep.27034","article-title":"Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice","volume":"60","author":"Zhang","year":"2014","journal-title":"Hepatology"},{"key":"2025120518011226000_7.9.e019022.80","doi-asserted-by":"crossref","first-page":"S607","DOI":"10.1016\/S0168-8278(16)01122-3","volume":"64","author":"Zhang","year":"2016","journal-title":"J Hepatol"},{"key":"2025120518011226000_7.9.e019022.81","first-page":"367","article-title":"The clinical observation of effect of lamivudine on interrupting mother to infant transmission of chronic HBV on 50 mothers","volume":"26","author":"Zhang","year":"2010","journal-title":"J Prat Obst Gynecol"},{"key":"2025120518011226000_7.9.e019022.82","unstructured":"Shi Z , Li X , Yang Y , et al . Clinical research on the interruption of mother to child transmissionof HBV- a randomized, double-blind, placebo-control study. 2008."},{"key":"2025120518011226000_7.9.e019022.83","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-3213"},{"key":"2025120518011226000_7.9.e019022.84","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/apt.13795","article-title":"Systematic review with meta-analysis: the risk of mother-to-child transmission of hepatitis B virus infection in sub-Saharan Africa","volume":"44","author":"Keane","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2025120518011226000_7.9.e019022.85","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39490.551019.BE"},{"key":"2025120518011226000_7.9.e019022.86","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.17.2203"},{"key":"2025120518011226000_7.9.e019022.87","unstructured":"World Health Organization. Press Release: First PROMISE study results confirm WHO recommendations to treat pregnant women and reduce mother-to-child-transmission of HIV. 2014 http:\/\/www.who.int\/hiv\/mediacentre\/news\/promise-study-result\/en\/ (accessed 28 Jul 2017)."},{"key":"2025120518011226000_7.9.e019022.88","unstructured":"Lack of clinically relevant drug-drug interactions between tenofovir DF and efavirenz, indinavir, lamivudine and lopinavir\/ritonavir in healthy subjects. 8th European Conference on Clinical Aspects and Treatment of HIV Infection."},{"key":"2025120518011226000_7.9.e019022.89","unstructured":"Pharmacokinetic drug interaction of lopinavir\/ritonavir in combination with tenofovir in experienced HIV+ patients [abstract A-445]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy."},{"key":"2025120518011226000_7.9.e019022.90","unstructured":"Comparison of lopinavir\/r plasma levels with and without tenofovir as part of HAART in HIV-1 infected patients. 5th International Workshop on Clinical Pharmacology of HIV Therapy."},{"key":"2025120518011226000_7.9.e019022.91","first-page":"278","article-title":"Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir\/ritonavir","volume":"43","author":"Kearney","year":"2006","journal-title":"JAIDS"},{"key":"2025120518011226000_7.9.e019022.92","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000243103.03265.2b"},{"key":"2025120518011226000_7.9.e019022.93","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181d6c9ed"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-019022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T02:01:23Z","timestamp":1764986483000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-019022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,11]]},"references-count":93,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9,11]]},"published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1136\/bmjopen-2017-019022"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-019022","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,11]]}}}